<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND AIMS: <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> predisposes to oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> but the majority of patients are undiagnosed </plain></SENT>
<SENT sid="1" pm="."><plain>A novel non-endoscopic cytological screening device, called a capsule sponge, makes population-based screening for the disease a feasible option </plain></SENT>
<SENT sid="2" pm="."><plain>However, due to the mixed cell population retrieved by the capsule sponge, biomarkers specific for <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> are required </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Three publically available microarray datasets were used to identify putative biomarkers present in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> but absent from <z:mpath ids='MPATH_458'>normal</z:mpath> oesophagus and gastric mucosa </plain></SENT>
<SENT sid="4" pm="."><plain>Validation was performed by qPCR (n = 10 each of <z:mpath ids='MPATH_458'>normal</z:mpath> oesophagus, <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, gastric mucosa) and immunohistochemistry (<z:mpath ids='MPATH_458'>normal</z:mpath> oesophagus, n = 20; <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, n = 21; gastric mucosa, n = 24; duodenum, n = 18) </plain></SENT>
<SENT sid="5" pm="."><plain>The biomarker was then prospectively evaluated on capsule sponge specimens from 47 patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and 99 healthy controls </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: 2/14 genes identified, <z:chebi fb="0" ids="49168">dopa</z:chebi> decarboxylase (<z:chebi fb="5" ids="10101">DDC</z:chebi>) and Trefoil factor 3 (TFF3), were confirmed by qPCR to be upregulated in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> compared to <z:mpath ids='MPATH_458'>normal</z:mpath> oesophagus (p&lt;0.01) and gastric mucosa (p&lt;0.01 and p&lt;0.05, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>Immunohistochemistry confirmed that <z:chebi fb="5" ids="10101">DDC</z:chebi> protein expression was restricted to <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> but was confined to &lt;1% of the cells within the crypt compartment </plain></SENT>
<SENT sid="8" pm="."><plain>TFF3 protein was expressed to high levels at the <z:chebi fb="2" ids="8069">luminal</z:chebi> surface of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> compared to absent expression in <z:mpath ids='MPATH_458'>normal</z:mpath> oesophagus and gastric mucosa (p&lt;0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Using the capsule sponge 36/46 patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (one inadequate sample) and 6/96 controls were positive for TFF3 giving a sensitivity of 78% and a specificity of 94% </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: TFF3 is a promising marker for <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> screening since it is expressed at the <z:chebi fb="2" ids="8069">luminal</z:chebi> surface of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> but not in adjacent tissue types and may be applied to a non-endoscopic screening device </plain></SENT>
</text></document>